These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 30826774

  • 1. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
    Dörner T, Posch MG, Li Y, Petricoul O, Cabanski M, Milojevic JM, Kamphausen E, Valentin MA, Simonett C, Mooney L, Hüser A, Gram H, Wagner FD, Oliver SJ.
    Ann Rheum Dis; 2019 May; 78(5):641-647. PubMed ID: 30826774
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
    Bowman SJ, Fox R, Dörner T, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki JN, Sopala MA, Luo WL, Hueber W.
    Lancet; 2022 Jan 08; 399(10320):161-171. PubMed ID: 34861168
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.
    Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, Desmoulins F, Nocturne G, Ravaud P, De Vita S.
    Ann Rheum Dis; 2015 Mar 08; 74(3):526-31. PubMed ID: 24347569
    [Abstract] [Full Text] [Related]

  • 4. Ianalumab (VAY736) in primary Sjögren's syndrome: assessing disease activity using multi-modal ultrasound.
    Diekhoff T, Fischer T, Schefer Q, Posch MG, Dörner T, Laurent D, Li Y, Wagner FD, Oliver SJ.
    Clin Exp Rheumatol; 2020 Mar 08; 38 Suppl 126(4):228-236. PubMed ID: 33095139
    [Abstract] [Full Text] [Related]

  • 5. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
    Meiners PM, Vissink A, Kroese FG, Spijkervet FK, Smitt-Kamminga NS, Abdulahad WH, Bulthuis-Kuiper J, Brouwer E, Arends S, Bootsma H.
    Ann Rheum Dis; 2014 Jul 08; 73(7):1393-6. PubMed ID: 24473674
    [Abstract] [Full Text] [Related]

  • 6. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM, Arends S, Brouwer E, Spijkervet FK, Vissink A, Bootsma H.
    Ann Rheum Dis; 2012 Aug 08; 71(8):1297-302. PubMed ID: 22258489
    [Abstract] [Full Text] [Related]

  • 7. Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome.
    Pontarini E, Fabris M, Quartuccio L, Cappeletti M, Calcaterra F, Roberto A, Curcio F, Mavilio D, Della Bella S, De Vita S.
    Rheumatology (Oxford); 2015 Aug 08; 54(8):1429-34. PubMed ID: 25740829
    [Abstract] [Full Text] [Related]

  • 8. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
    Liu X, Li X, Li X, Li Z, Zhao D, Liu S, Zhang M, Zhang F, Zhu P, Chen J, Wei W, Lin B, Zhou Y, Chen J, Pang Y, Zhang L, Sun X, Yu Z, Jia Y, Wang J, Sun W, Chiu F, Pang L, Wang G.
    Clin Rheumatol; 2019 Mar 08; 38(3):657-664. PubMed ID: 30280368
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
    Baer AN, Gottenberg JE, St Clair EW, Sumida T, Takeuchi T, Seror R, Foulks G, Nys M, Mukherjee S, Wong R, Ray N, Bootsma H.
    Ann Rheum Dis; 2021 Mar 08; 80(3):339-348. PubMed ID: 33168545
    [Abstract] [Full Text] [Related]

  • 10. Clinical and immunological consequences of total glucosides of paeony treatment in Sjögren's syndrome: A randomized controlled pilot trial.
    Zhou Y, Jin L, Kong F, Zhang H, Fang X, Chen Z, Wang G, Li X, Li X.
    Int Immunopharmacol; 2016 Oct 08; 39():314-319. PubMed ID: 27517517
    [Abstract] [Full Text] [Related]

  • 11. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
    Cornec D, Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, Le Guern V, Sibilia J, Gottenberg JE, Chiche L, Hachulla E, Yves Hatron P, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost JJ, Saliou P, Pers JO, Seror R, Saraux A.
    Arthritis Care Res (Hoboken); 2017 Apr 08; 69(4):528-535. PubMed ID: 27390310
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial.
    Shao Q, Wang S, Jiang H, Liu L.
    Scand J Rheumatol; 2021 Mar 08; 50(2):143-152. PubMed ID: 33118847
    [Abstract] [Full Text] [Related]

  • 13. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
    Park EH, Ha YJ, Kang EH, Song YW, Scofield RH, Lee YJ.
    Rheumatology (Oxford); 2021 Jun 18; 60(6):2714-2724. PubMed ID: 33188390
    [Abstract] [Full Text] [Related]

  • 14. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
    Cornec D, Costa S, Devauchelle-Pensec V, Jousse-Joulin S, Marcorelles P, Berthelot JM, Chiche L, Hachulla E, Hatron PY, Goeb V, Vittecoq O, Saraux A, Pers JO.
    J Autoimmun; 2016 Feb 18; 67():102-110. PubMed ID: 26688003
    [Abstract] [Full Text] [Related]

  • 15. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
    Juarez M, Diaz N, Johnston GI, Nayar S, Payne A, Helmer E, Cain D, Williams P, Devauchelle-Pensec V, Fisher BA, Giacomelli R, Gottenberg JE, Guggino G, Kvarnström M, Mariette X, Ng WF, Rosas J, Sánchez Bursón J, Triolo G, Barone F, Bowman SJ.
    Rheumatology (Oxford); 2021 Mar 02; 60(3):1364-1375. PubMed ID: 32949140
    [Abstract] [Full Text] [Related]

  • 16. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.
    Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, Richards A, Rauz S, Emery P.
    Ann Rheum Dis; 2008 Nov 02; 67(11):1541-4. PubMed ID: 18276741
    [Abstract] [Full Text] [Related]

  • 17. The efficacy and mechanism for action of iguratimod in primary Sjögren's syndrome patients.
    Jiang W, Zhang L, Zhao Y, He X, Hu C, Liu Y.
    Int Ophthalmol; 2020 Nov 02; 40(11):3059-3065. PubMed ID: 32607949
    [Abstract] [Full Text] [Related]

  • 18. Targeted Therapy for Primary Sjögren's Syndrome: Where are We Now?
    Wang B, Chen S, Li Y, Xuan J, Liu Y, Shi G.
    BioDrugs; 2021 Nov 02; 35(6):593-610. PubMed ID: 34731460
    [Abstract] [Full Text] [Related]

  • 19. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study.
    Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM, Pradier O.
    Arthritis Res Ther; 2006 Nov 02; 8(4):R129. PubMed ID: 16859536
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.
    De Vita S, Quartuccio L, Seror R, Salvin S, Ravaud P, Fabris M, Nocturne G, Gandolfo S, Isola M, Mariette X.
    Rheumatology (Oxford); 2015 Dec 02; 54(12):2249-56. PubMed ID: 26242856
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.